Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib Plus Bortezomib in AML
NCT00510939Phase 2Unknown
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in acute myeloid leukemia (AML), sponsored by Alma Mater Studiorum – Università di Bologna. Status: unknown.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00510939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510939.